S1PR2 and periodontitis: Because treatment with JTE013 inhibited inflammation, attenuated osteoclastogenesis, promoted angiogenesis, and induced bone healing, inhibition of S1PR2 by JTE013 may potentially serve as a therapeutic strategy to treat inflammatory bone loss diseases, including periodontitis.